timothy sykes logo

Stock News

Could Longboard Pharmaceuticals’ Recent FDA Approvals Propel Its Stock Price?

Timothy SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Could Longboard Pharmaceuticals’ Recent FDA Approvals Propel Its Stock Price? Thumbnail

Longboard Pharmaceuticals Inc.’s stock surged after the announcement of promising clinical trial results for their neurotherapeutic drug, capturing market attention. On Monday, Longboard Pharmaceuticals Inc.’s stocks have been trading up by 51.65 percent.

Breaking Developments in Longboard Pharmaceuticals

  • The FDA has granted Longboard’s bexicaserin drug both rare pediatric disease and orphan drug designations for treating Dravet syndrome, a significant step in its epilepsy treatment journey.
  • Analysts at H.C. Wainwright have raised the price target on Longboard to $80 from $60, after promising outcomes from its Phase 2 discussions with the FDA about developing drugs for epileptic encephalopathies.
  • Longboard’s initiation of the global DEEp SEA Study seeks to evaluate bexicaserin for Dravet syndrome, involving approximately 160 participants across a broad age range.

Candlestick Chart

Live Update at 16:03:32 EST: On Monday, October 14, 2024 Longboard Pharmaceuticals Inc. stock [NASDAQ: LBPH] is trending up by 51.65%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Longboard’s Financial Pulse and What It Means

In the quarter ending June 30, 2024, Longboard Pharmaceuticals Inc. demonstrated notable resilience, though the numbers revealed some grim realities. Revenue figures remain undisclosed, yet there’s a clear sign of struggle when glancing at profitability ratios which show they are currently not turning a profit. Their EBITDA marked negative $19.934 M—a challenge mirrored by their net income which hit a low of -$21.785 M.

The company’s financial strength, however, shines through a stellar current ratio of 21 indicating they’ve got cash and assets with enough strength to handle liabilities. The enterprise value stands at a sizable $1.035 billion, showcasing the inherent market belief in Longboard’s potential future growth, especially with their exciting drug development pipeline.

More Breaking News

It’s almost like watching an underdog’s tale unfold; despite present hurdles, Longboard seems poised for a potential turnaround. Analysts’ upbeat price revaluations add a hopeful underscore, doubling down on the belief that Longy, as some investors call it, might just surprise its naysayers.

Spotlight on Key News Enhancing Market Dynamics

Longboard’s announcement of Phase 3 DEEp SEA Study for their drug bexicaserin is remarkable news. The DEEp SEA Study is not just another research endeavour; it’s a critical milestone for a drug addressing Dravet syndrome, a rare disorder. Through a global, double-blind, meticulously controlled trial, Longboard plans to ascertain bexicaserin’s potency. Investing nearly a lifetime of research and hope is like betting on a trusted racehorse in a gritty derby. A gamble, but with a growing percent of winning odds.

Furthermore, recent FDA approvals inject a potent catalyst into Longboard’s market narrative. With the FDA giving a nod for orphan and rare pediatric disease status, bexicaserin is now positioned uniquely—meaning potential market exclusivity and faster pathways. It’s like clearing a freeway lane, allowing Longboard to accelerate production and hurdles post-drug approval.

The analyst upgrades from H.C. Wainwright subsequently reaffirm belief in Longboard’s strategic directions. An adjustment in stock target price signifies bolstered confidence and can often free up additional resources and steer investor attention—a chance to gather collective buy-ins and propel stock momentum upwards.

Summary and Reflections on the Financial Horizon

Longboard’s journey through the intricate web of pharmaceuticals finds them at a noteworthy junction. While financial sheets reflect dare we say, ordinary revenues and an unsteady profit margin, the stories aren’t just in the numbers. They’re in the trials initiated, the regulatory approvals won, and the perception this instills among market players.

As some investors might say, it’s not how quickly you shine in medicinal innovation, but how brightly. And Longboard, with an impressive arsenal of drug designs and strategic FDA approvals, now lights up the path with an incandescent glow. Keeping an eye on how Longboard maneuvers through Q3 financials, what decisions compel them forward, and how those pharmacist dreams translate into empirical realities will be pivotal in judging whether this stock’s journey is genuinely upward bound.

In conclusion, will Longboard’s strategic FDA captures alongside their promising drug trials script a turnaround epic for the ages? The elements are there. The anticipation builds. The stakes are set. As goes the venerable Wall Street question of when to sell or hold, that decision rests as much with the heart of a trader as with the spirit of analytical acumen.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Our traders will never trade any stock until they see a setup they like. Their strategy is to capture short-term momentum while avoiding undue risk exposure to a stock’s long-term volatility. This method is especially useful when trading penny stocks or other high-risk equities, where rapid gains can be made by understanding stock patterns, manipulation, and media hype. Whether you are an active day trader looking for key indicators on a stock’s next move, or an investor doing due diligence before entering a position, Timothy Sykes News is designed to help you make informed trading decisions.

Curious about this stock and eager to learn more? Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success. Start your journey towards financial growth and trading mastery!

But wait, there’s more! Elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade harnesses the power of Artificial Intelligence to guide you through the market’s twists and turns. Discover insights on Robinhood penny stocks and top biotech picks to fuel your trading journey:

Ready to embark on your financial adventure? Click the links and let the journey unfold.

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”